dc.contributor.author | CAYCI, Yeliz Tanriverdi | |
dc.contributor.author | Gunaydin, Murat | |
dc.contributor.author | Yilmaz, Hava | |
dc.contributor.author | Karadag, Adil | |
dc.contributor.author | Esen, Saban | |
dc.contributor.author | Yanik, Kerametrin | |
dc.date.accessioned | 2021-03-04T15:00:46Z | |
dc.date.available | 2021-03-04T15:00:46Z | |
dc.date.issued | 2014 | |
dc.identifier.citation | Yanik K., Yilmaz H., CAYCI Y. T. , Karadag A., Esen S., Gunaydin M., "GLYCOPEPTIDES AND LINEZOLID MIC CHANGES IN STAPHYLOCOCCUS AUREUS AND COAGULASE NEGATIVE STAPHYLOCOCCI ISOLATES FROM 2008-2011", ACTA MEDICA MEDITERRANEA, cilt.30, sa.5, ss.993-996, 2014 | |
dc.identifier.issn | 0393-6384 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_848b08d9-5498-4d0c-9ced-655965a5bdd2 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/90151 | |
dc.description.abstract | Aims: Glycopeptides and linezolid are the antimicrobial agents used for the treatment of methicillin resistant Staphylococcus aureus (MRSA) and methicillin resistant Coagulase negative Staphylococci (MRCoNS) infections. It is emerging concern about an increase minimum inhibitor concentration (MIC) of vacomycin among S. aureus strains. In this study, we aimed to analyse the trends in MICs of vancomycin, teicoplanin and linezolid over 4 years (2008-2011) period. | |
dc.language.iso | eng | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Temel Tıp Bilimleri | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | TIP, GENEL & İÇECEK | |
dc.title | GLYCOPEPTIDES AND LINEZOLID MIC CHANGES IN STAPHYLOCOCCUS AUREUS AND COAGULASE NEGATIVE STAPHYLOCOCCI ISOLATES FROM 2008-2011 | |
dc.type | Makale | |
dc.relation.journal | ACTA MEDICA MEDITERRANEA | |
dc.contributor.department | Ondokuz Mayıs Üniversitesi , , | |
dc.identifier.volume | 30 | |
dc.identifier.issue | 5 | |
dc.identifier.startpage | 993 | |
dc.identifier.endpage | 996 | |
dc.contributor.firstauthorID | 93419 | |